Organon & Co. develops and delivers women health solutions through prescription therapies and medical devices in the United States, Europe, Canada, Japan, rest of the Asia Pacific, China, Latin America, the Middle East, Russia, Africa, and internationally. The company's women's health portfolio comprises contraception and fertility brands, such as Nexplanon, a long-acting reversible contraceptive; NuvaRing, a monthly vaginal contraceptive ring; Cerazette, Marvelon, and Mercilon, which are daily pills used to prevent pregnancy; Follistim AQ, which is used to promote the development of multiple ovarian follicles in medically assisted reproduction procedures; Elonva, a follicle stimulant; Ganirelix acetate injection, an injectable antagonist; Jada for abnormal postpartum uterine bleeding and hemorrhage; and Xaciato for bacterial vaginosis. Its biosimilars portfolio consists of immunology products, such as Brenzys, Renflexis, and Hadlima; oncology products, including Ontruzant and Aybintio; Bildyos and Bilprevda, a recombinant anti-RANKL human monoclonal antibodies; and Poherdy, a neu receptor antagonist. The company also offers cholesterol-modifying medicines under the Zetia, Ezetrol, Vytorin, Inegy, Atozet, Rosuzet, and Zocor brands; Cozaar and Hyzaar for hypertension; respiratory products used to control and prevent asthma-induced symptoms under the Singulair, Dulera, Zenhale, and Asmanex brands, as well as seasonal allergic rhinitis under the Nasonex, Clarinex, and Aerius brands. In addition, it provides dermatology products under the Vtama, Diprosone, and Elocon brand; bone health products under the Fosamax brand; and non-opioid pain management products under the Arcoxia, Diprospan, and Celestone brands, as well as Proscar for symptomatic benign prostatic hyperplasia; and Propecia for male pattern hair loss. The company serves drug wholesalers and retailers, hospitals, clinics, government agencies, health maintenance organizations, pharmacy benefit managers, and other institutions. Organon & Co. was founded in 1
The current price of 7XP.STU is €7.58 EUR — it has increased by +29.02% in the past 24 hours. Watch Organon stock price performance more closely on the chart.
What is Organon stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Organon stocks are traded under the ticker 7XP.STU.
Is Organon stock price growing?▼
7XP.STU stock has risen by +38.04% compared to the previous week, the month change is a +36.99% rise, over the last year Organon has showed a -22.28% decrease.
When is the next Organon earnings date?▼
Organon is going to release the next earnings report on April 30, 2026.
What were Organon earnings last quarter?▼
7XP.STU earnings for the last quarter are 0.53 EUR per share, whereas the estimation was 0.61 EUR resulting in a -13.34% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Organon have?▼
As of April 11, 2026, the company has 10,000 employees.
In which sector is Organon located?▼
Organon operates in the Other sector.
When did Organon complete a stock split?▼
Organon has not had any recent stock splits.
Where is Organon headquartered?▼
Organon is headquartered in Jersey City, United Kingdom.